Atosiban Acetate Cas No. 914453-95-5
Product source: Chemical synthesis
Product content: ≥ 98%
CAS NO：914453-95-5
Detection method: HPLC
Active ingredient: cyclic nonapeptide
Molecular formula: C45H71N11O14S2
Molecular weight: 1054.25
Product Description: White to off white crystalline powder, easily soluble in water
Product usage: scientific research, pharmaceuticals
Product packaging: 1 mg -10 g; Optional 1g bottle, 10g bottle, 50g bottle, etc
Product storage: -20 ℃, sealed in the dark (dry); Partial suggestion: Refrigeration at 2-8 ℃
Shelf life: 24 months
Atosiban Acetate API Powder | CAS 914453-95-5 | Selective Oxytocin Antagonist
Atosiban Acetate (CAS No. 914453-95-5) is a synthetic cyclic nonapeptide that functions as a highly selective competitive antagonist of human oxytocin and vasopressin V1A receptors. Specifically engineered to delay imminent preterm birth, it provides a superior safety profile by targeting the myometrium without the cardiovascular complications typical of adrenergic agonists. Manufactured under rigorous cGMP protocols at Xi'an Tihealth, our Atosiban Acetate achieves a validated HPLC purity of $\ge$ 98.0%, with ultra-low impurity profiles. This pharmaceutical-grade API is optimized for the production of sterile intravenous bolus and infusion solutions, ensuring exceptional batch-to-batch consistency and high water solubility ($\ge$ 50 mg/mL).
How does Atosiban Acetate facilitate the rapid inhibition of uterine contractions?
Atosiban Acetate exerts its tocolytic effect through a precise multi-target receptor antagonism on the uterine smooth muscle:
- Competitive Receptor Binding: It binds with high affinity to oxytocin receptors (OXTR) and vasopressin V1A receptors in the myometrium and decidua, preventing the docking of endogenous oxytocin.
- Intracellular Signaling Blockade: By inhibiting the Gq-protein pathway, it reduces the production of inositol triphosphate (IP3), effectively blocking the release of $Ca^{2+}$ from the sarcoplasmic reticulum.
- Calcium Influx Reduction: It suppresses the opening of voltage-gated calcium channels, leading to a significant decrease in extracellular calcium influx and immediate relaxation of uterine smooth muscle fibers.
What are the primary clinical indications and industrial applications?
- Preterm Labor Management: The foundational API for manufacturing intravenous treatments indicated for pregnant women (24–33 weeks gestation) to prolong pregnancy and allow for fetal lung maturation.
- Assisted Reproductive Technology (ART): Utilized in R&D to improve embryo implantation rates by reducing uterine contractions during embryo transfer.
- Sterile Injectable Formulation: High-specification lyophilized powder optimized for rapid reconstitution in normal saline or glucose solutions.
Compliance & Stability Notice: Atosiban Acetate is a sensitive peptide API. Storage at -20°C in airtight, light-protected containers is mandatory for long-term potency. To maintain its validated 24-month shelf life, avoid exposure to moisture and maintain a nitrogen-flushed environment upon opening.
What is the validated toxicological and safety profile of this API?
Systemic Safety: Preclinical studies in dogs and rats at 10x the therapeutic human dose showed no significant organ-specific pathology over 3 months.
Reproductive Integrity: Extensive testing confirms no evidence of genetic mutations, carcinogenicity, or fetal malformations (Ames and chromosomal aberration tests negative). Its cardiovascular profile remains significantly more stable than traditional tocolytics.
Frequently Asked Questions (FAQ)
Unlike Beta-agonists, which act on receptors throughout the body, Atosiban is highly specific to the myometrium. This specificity results in far fewer maternal side effects, such as tachycardia, palpitations, and pulmonary edema, making it a safer clinical choice for high-risk pregnancies.
What is the solubility profile of Xi'an Tihealth's Atosiban API?
Our Atosiban Acetate powder is highly hydrophilic, with a validated solubility of ≥ 50 mg/mL in water. This ensures rapid dissolution and excellent clarity when formulated into saline-based intravenous bolus injections or glucose-based infusions.
How do you maintain the stability of this cyclic nonapeptide?
The stability of Atosiban is maintained through advanced solid-phase peptide synthesis (SPPS) and strict temperature control. We recommend long-term storage at -20°C in a dry, nitrogen-sealed environment to prevent peptide chain degradation or disulfide bridge oxidation.
Can Atosiban API be used in embryo transfer protocols?
Yes. Emerging research and clinical applications in IVF centers utilize Atosiban to reduce uterine contractility during the embryo transfer phase, which can potentially improve the clinical pregnancy rate in patients with frequent uterine contractions.
Hot Tags: atosiban acetate cas no. 914453-95-5, China atosiban acetate cas no. 914453-95-5 manufacturers, suppliers, factory
You Might Also Like
Send Inquiry